Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs VREX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 3–7 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 5 – 1 VREX Matrix Metrics: DCTH 3 – 7 VREX

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Varex Imaging Corporation (VREX) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas VREX carries 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin).

  • Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 8.3% operating margin) and revenue trajectory (+70.7% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile VREX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs VREX
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
VREX NASDAQ
Varex Imaging Corporation Common Stock
Electronic Components, Nec
$18.21
+0.64% 1D
Market Cap $771.6M
TTM Revenue $865M
Forward P/E 16.9x
Beta / 30D Vol 0.74β · 5% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 47.0 Fund 50.0 Flow 50.0 Mom 56.1
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.2%) with fading momentum, RSI 36
RSI-14: 35.5 · SMA20: $18.40 · SMA50: $18.44

6-Pillar Scorecard Institutional Category Breakdown (DCTH 5 – 1 VREX)

Columns: Metric · DCTH · VREX
1. Valuation Multiples VREX
Forward P/E N/M 16.9x
Trailing P/E 133.6x 34.3x
PEG Ratio 1.60x 6.30x
EV / Revenue 6.3x 0.9x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +3.7%
Earnings Growth (YoY) +750.0% +453.4%
TTM Revenue (USD) $110M $865M
Market Cap $743.8M $771.6M
3. Profitability & Quality DCTH
Gross Margin 87.6% 34.3%
Operating Margin 5.2% 8.3%
Net Profit Margin 6.0% 2.6%
Return on Equity (ROE) 5.4% 4.6%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M $100M EBITDA
Cash Flow Margin 18.3% 11.5% EBITDA Mgn
Net Cash / Leverage $53M Net Cash $11.78 Book/Sh · 4.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 109.3% (43rd %ile) 112.0% (18th %ile)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) 26.0% of Rev ($225M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (3) vs VREX (7)
Institutional Metric DCTH VREX Criterion Row Edge
Market Capitalization
Scale
$743.8M $771.6M Larger Scale VREX
Trailing P/E Ratio
Valuation
133.6x 34.3x Lower Multiple VREX
Forward P/E Ratio
Valuation
N/M 16.9x Lower Multiple VREX
Revenue Growth (YoY)
Growth
+70.7% +3.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% 8.3% Higher Margin VREX
Net Profit Margin
Profitability
6.0% 2.6% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% 4.6% Higher ROE DCTH
52-Week Range Position
Momentum
80% ($8–$23) 96% ($9–$19) Stronger Trend VREX
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 0.74β · 5% Vol Lower Realized Risk VREX
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 50.0 / 100 (HOLD) Higher Composite VREX
Trailing 12M Revenue (USD)
Operating Scale
$110M $865M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 34.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev 6.30x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) $100M EBITDA ($11.78 Book/Sh · 4.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +40.83 pp
DCTH: +39.77% · VREX: -1.06%
3M Horizon DCTH +18.06 pp
DCTH: +16.73% · VREX: -1.33%
6M Horizon VREX +10.32 pp
DCTH: +77.46% · VREX: +87.78%
1Y Horizon DCTH +77.03 pp
DCTH: +128.57% · VREX: +51.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DCTH vs VREX. Trailing 12-month operating profitability (DCTH 5.2% vs VREX 8.3%) and valuation multiples (DCTH N/M vs VREX 16.9x Forward P/E) are benchmarked directly in Pillar 4 below.

DCTH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$110M
Gross Margin87.6%
Op. Margin5.2%
ROE / Fwd P/E5.4% · N/M
VREX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$865M
Gross Margin34.3%
Op. Margin8.3%
ROE / Fwd P/E4.6% · 16.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VREX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 112.0%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VREX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
VREX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $771.6M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 26.0% of Rev ($225M)
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs VREX Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Varex Imaging Corporation (VREX) in the Tradestie Institutional Equity Comparison Engine, winning 3–7 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas VREX carries 50.0/100 (HOLD) at $18.21 (16.9x Forward P/E, 8.3% operating margin). Composite vs. Pillar Nuance: While VREX currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (3–7 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (5.2% vs. 8.3% operating margin) and revenue trajectory (+70.7% vs. +3.7% YoY). Technical & Structure Timing Caution: DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9); meanwhile VREX is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with VREX at +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin). On trailing 12-month operating scale, DCTH generates $110M in USD-normalized revenue versus $865M for VREX. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus 26.0% of Rev ($225M) (0 disclosures) for VREX.

VREX screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas VREX trades at 16.9x Forward P/E, 34.3x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus VREX (4.6% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.74β · 5% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.